<DOC>
	<DOC>NCT01842893</DOC>
	<brief_summary>The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.</brief_summary>
	<brief_title>Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Inclusion criteria: 1. Written informed consent 2. Malignant solid tumor or a hematological malignancy causing cancerrelated pain 3. Background opioid treatment at a stable dose for at least a week 4. One to four episodes of breakthrough pain per day Main exclusion criteria: 1. Hypersensitivity to fentanyl or to any of the excipients 2. Intrathecal opioids 3. Recent history of substance abuse 4. Recent or planned therapy that would alter pain 5. Moderate or severe hepatic or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>fentanyl</keyword>
	<keyword>breakthrough pain</keyword>
	<keyword>opioid treated cancer patients</keyword>
</DOC>